Galderma Leads in Aesthetic Injectables for Weight Loss With New Research & Guidelines

Galderma, a global leader in dermatology, is pioneering research into the effects of medication-driven weight loss on the skin and the importance of incorporating aesthetic treatments into the patient journey. As the prevalence of prescription weight loss medications grows, with…

Read MoreGalderma Leads in Aesthetic Injectables for Weight Loss With New Research & Guidelines

Virpax Pharmaceuticals, Inc. Prices $6 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals Announces Public Offering Pricing to Fuel Drug Development and Innovation Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), a forward-thinking preclinical-stage pharmaceutical company specializing in groundbreaking drug delivery systems for pain management, has unveiled the pricing details of its latest public…

Read MoreVirpax Pharmaceuticals, Inc. Prices $6 Million Public Offering of Common Stock and Pre-Funded Warrants

Inventia Life Science Unveils RASTRUM™ Allegro to Transform High-Throughput 3D Cell Culture in Drug Discovery and Disease Research

Inventia Life Science Unveils RASTRUM™ Allegro to Transform High-Throughput 3D Cell Culture in Drug Discovery and Disease Research Inventia Life Science Unveils RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research Inventia Life Science, a…

Read MoreInventia Life Science Unveils RASTRUM™ Allegro to Transform High-Throughput 3D Cell Culture in Drug Discovery and Disease Research

RenovoRx Showcases Promising Pharmacokinetic Data at ASCO GI 2025

Introduction to RenovoRx and Its Innovative TAMP™ Therapy RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company dedicated to revolutionizing oncology treatment, recently shared compelling data from its novel therapeutic platform at the ASCO Gastrointestinal Cancers Symposium…

Read MoreRenovoRx Showcases Promising Pharmacokinetic Data at ASCO GI 2025

Senior Care Partners (PACE) Enhances Elderly Patient Safety with DoseMeRx

Senior Care Partners (PACE) Enhances Elderly Patient Safety with DoseMeRx DoseMeRx Empowers Senior Care Partners (PACE) to Improve Elderly Patient Safety with Modernized Vancomycin Dosing DoseMe, a recognized leader in model-informed precision dosing (MIPD), has announced that Senior Care Partners…

Read MoreSenior Care Partners (PACE) Enhances Elderly Patient Safety with DoseMeRx

Bristol Myers Squibb Presents CheckMate-8HW Results: Opdivo® Plus Yervoy® vs. Opdivo Monotherapy

Bristol Myers Squibb Presents Results from CheckMate-8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in MSI-H/dMMR Metastatic Colorectal Cancer Bristol Myers Squibb (NYSE: BMY) has announced results from an analysis of the three-arm Phase 3 CheckMate-8HW…

Read MoreBristol Myers Squibb Presents CheckMate-8HW Results: Opdivo® Plus Yervoy® vs. Opdivo Monotherapy

Exelixis Reports Positive STELLAR-001 Results for Zanzalintinib in Metastatic CRC at ASCO GI 2025

Exelixis Reports Positive STELLAR-001 Results for Zanzalintinib in Metastatic CRC at ASCO GI 2025 Exelixis Announces Promising Results from Phase 1b/2 STELLAR-001 Trial for Zanzalintinib in Metastatic Colorectal Cancer at ASCO GI 2025 Exelixis, Inc. (Nasdaq: EXEL) recently presented data…

Read MoreExelixis Reports Positive STELLAR-001 Results for Zanzalintinib in Metastatic CRC at ASCO GI 2025